BNP Paribas Financial Markets Has $30.35 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

BNP Paribas Financial Markets increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 111.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 213,992 shares of the company’s stock after purchasing an additional 113,017 shares during the period. BNP Paribas Financial Markets’ holdings in Neurocrine Biosciences were worth $30,350,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of Neurocrine Biosciences by 11.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after acquiring an additional 468,405 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 83.7% during the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after acquiring an additional 1,263,633 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after acquiring an additional 34,457 shares in the last quarter. Deerfield Management Company L.P. boosted its position in shares of Neurocrine Biosciences by 1.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock worth $166,258,000 after acquiring an additional 16,543 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter worth approximately $162,664,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $167.35 on Friday. The company has a market cap of $16.83 billion, a price-to-earnings ratio of 25.79, a PEG ratio of 1.24 and a beta of 0.40. The firm has a 50 day simple moving average of $142.08 and a 200 day simple moving average of $139.54. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $169.57.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 36,937 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total value of $5,770,298.14. Following the completion of the transaction, the insider directly owned 22,374 shares in the company, valued at approximately $3,495,266.28. This represents a 62.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the completion of the transaction, the director owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This trade represents a 32.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 328,984 shares of company stock worth $50,986,985. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on NBIX shares. Leerink Partners increased their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a research note on Tuesday. They issued a “buy” rating and a $213.00 price objective for the company. Wedbush increased their price objective on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their price objective on shares of Neurocrine Biosciences from $180.00 to $183.00 and gave the company an “outperform” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $187.52.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.